Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + paclitaxel + carboplatin + cisplatin
- Development stage
- Phase 3
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination therapy consisting of pembrolizumab (an anti-PD-1 monoclonal antibody) with chemotherapy agents paclitaxel, carboplatin, and cisplatin. The combination is being studied for various cancer types including head and neck squamous cell carcinoma (HNSCC), endometrial cancer, and cervical cancer. Pembrolizumab works by blocking the PD-1 pathway, enhancing the immune system's ability to detect and fight cancer cells. The chemotherapy components (paclitaxel, carboplatin, and cisplatin) work in different ways to stop the growth of tumor cells, either by killing them or stopping them from dividing.
02
Targets
DNAMicrotubulePDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on pembrolizumab + paclitaxel + carboplatin + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + paclitaxel + carboplatin + cisplatin.